Author:
Chernysheva Anna M.,Degtereva Ekaterina A.,Chernikov Sergey U.
Abstract
The development of strategic alliances between Russian and foreign pharmaceutical companies allows not only to introduce biotechnologies in the domestic market, but also to strengthen the policy of import substitution and increase export volumes. That is why it is important to support the creation and functioning of strategic alliances at the state level. The purpose of this article is to study the creation and development of strategic alliances between Russia and Hungary, paying attention to the formation of alliances in the field of pharmaceuticals. In order to achieve this goal, the indicators of export-import operations between Russia and Hungary in the field of “pharmaceutical products”, as well as the main strategic alliances operating between the two countries were considered. It is assumed that the development of Russian-Hungarian strategic alliances in the field of pharmaceuticals with localization of production will help to achieve the goals of the import substitution policy in the field of drug production, as well as to intensify export operations. To test this hypothesis, documents published in the public domain were analyzed, including statistical data on export-import operations in the pharmaceutical market between Russia and Hungary. In general, it was proved that at the present stage of development of the pharmaceutical market of the Russian Federation, it is important to support the creation and functioning of strategic alliances, which will strengthen Russian positions not only in the domestic market, but also in the international market. Thus, the Russian Federation should actively develop and support the development of localized strategic alliances using various methods, which will increase the share of domestic biotechnologies and ensure their export.
Publisher
Peoples' Friendship University of Russia
Reference9 articles.
1. Balakin, K. V., Aiginin, A. A., & Ivashchenko, A. A. (2021). Russian pharmaceutical industry in the horizon 2030. Analytical review. Dolgoprudniy. 62
2. Bykova, E. A. Innovative processes in the Russian pharmaceutical market (2020). Bulletin of the University, (8), 57-64. (In Russ.) https://doi.org/10.26425/1816-4277-2020-8-57-64
3. Chaplenko, A. A., Vlasov, V. V., & Gildeeva, G. N. (2020). Innovative drugs in the Russian pharmaceutical market: key players and main directions of development. Journal Remedium, 10, 4-9. (In Russ.) https://doi.org/10.21518/1561-5936-2020-10-4-9
4. Gusakov, N. P., & Andronova, I. V. (2014). Common industrial policy: foreign practice and the experience for CIS. RUDN Journal of Economics, (3), 5-17. (In Russ.)
5. Nekhoda Ye. V., Redchikova N. A., & Tyuleneva N. A. (2018). Business Models of Companies: From Profit to Sustainable Development and Value Creation. Upravlenets - The Manager, 9(4), 9-19. https://doi.org/10.29141/2218-5003-2018-9-4-2
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献